Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium bifidum BD-1
- Development stage
- Preclinical
- Lead developer
- Sichuan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium bifidum BD-1 (BD-1) is a specific strain of probiotic bacteria originally isolated from the intestines of healthy infants in China. [2, 8] It is classified as a biologic (live bacterial strain) and is being investigated for its potential preventive and therapeutic effects on inflammatory bowel disease (IBD), particularly long-term colitis. [2] The proposed mechanism of action involves remodeling the gut microbiota, enhancing the intestinal barrier, and modulating the host's immune response. [2, 11] Preclinical research in mouse models has demonstrated that early-life administration of BD-1 can protect against chemically-induced colitis by reducing inflammation, promoting the expression of proteins related to the mucosal barrier (such as MUC2, ZO-1, and occludin), and altering the composition of gut bacteria. [2] As of now, it appears to be primarily a research compound, as no specific pharmaceutical developer or commercial brand name has been identified in the available literature.
Beyond the preview
Go deeper on bifidobacterium bifidum BD-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium bifidum BD-1.